|
1
|
Allemani C, Matsuda T, Di Carlo V,
Harewood R, Matz M, Nikšić M, Bonaventure A, Valkov M, Johnson CJ,
Estève J, et al: Global surveillance of trends in cancer survival
2000–14 (CONCORD-3): Analysis of individual records for 37 513 025
patients diagnosed with one of 18 cancers from 322 population-based
registries in 71 countries. Lancet. 391:1023–1075. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Siegel RL, Miller KD, Fedewa SA, Ahnen DJ,
Meester RGS, Barzi A and Jemal A: Colorectal cancer statistics,
2017. CA Cancer J Clin. 67:177–193. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhang J, Cheng Z, Ma Y, He C, Lu Y, Zhao
Y, Chang X, Zhang Y, Bai Y and Cheng N: Effectiveness of screening
modalities in colorectal cancer: A network meta-analysis. Clin
Colorectal Cancer. 16:252–263. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Banasiewicz T, Marciniak R, Kaczmarek E,
Krokowicz P, Paszkowski J, Lozynska-Nelke A, Gronek P, Plawski A
and Drews M: The prognosis of clinical course and the analysis of
the frequency of the inflammation and dysplasia in the intestinal
J-pouch at the patients after restorative proctocolectomy due to
FAP. Int J Colorectal Dis. 26:1197–1203. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fung KY, Dai L and Trimble WS: Cell and
molecular biology of septins. Int Rev Cell Mol Biol. 310:289–339.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Menon MB and Gaestel M: Sep(t)arate or
not-how some cells take septin-independent routes through
cytokinesis. J Cell Sci. 128:1877–1886. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cortez BA, Rezende-Teixeira P, Redick S,
Doxsey S and Machado-Santelli GM: Multipolar mitosis and aneuploidy
after chrysotile treatment: A consequence of abscission failure and
cytokinesis regression. Oncotarget. 7:8979–8992. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Poüs C, Klipfel L and Baillet A:
Cancer-related functions and subcellular localizations of septins.
Front Cell Dev Biol. 4:1262016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
McQuilken M, Jentzsch MS, Verma A, Mehta
SB, Oldenbourg R and Gladfelter AS: Analysis of septin
reorganization at cytokinesis using polarized fluorescence
microscopy. Front Cell Dev Biol. 5:422017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Menon MB and Gaestel M: Editorial:
Emerging functions of septins. Front Cell Dev Biol. 5:732017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Neubauer K and Zieger B: The mammalian
septin interactome. Front Cell Dev Biol. 5:32017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Estey MP, Di Ciano-Oliveira C, Froese CD,
Fung KY, Steels JD, Litchfield DW and Trimble WS: Mitotic
regulation of SEPT9 protein by cyclin-dependent kinase 1 (Cdk1) and
Pin1 protein is important for the completion of cytokinesis. J Biol
Chem. 288:30075–30086. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou XZ and Lu KP: The isomerase PIN1
controls numerous cancer-driving pathways and is a unique drug
target. Nat Rev Cancer. 16:463–478. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu M, Shen S, Chen F, Yu W and Yu L:
Linking the septin expression with carcinogenesis. Mol Biol Rep.
37:3601–3608. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Angelis D and Spiliotis ET: Septin
mutations in human cancers. Front Cell Dev Biol. 4:1222016.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Cerveira N, Santos J, Bizarro S, Costa V,
Ribeiro FR, Lisboa S, Correia C, Torres L, Vieira J, Snijder S, et
al: Both SEPT2 and MLL are down-regulated in MLL-SEPT2
therapy-related myeloid neoplasia. BMC Cancer. 9:1472009.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yu J, Zhang W, Tang H, Qian H, Yang J, Zhu
Z, Ren P and Lu B: Septin 2 accelerates the progression of biliary
tract cancer and is negatively regulated by mir-140-5p. Gene.
589:20–26. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kočevar N, Odreman F, Vindigni A, Grazio
SF and Komel R: Proteomic analysis of gastric cancer and immunoblot
validation of potential biomarkers. World J Gastroenterol.
18:1216–1228. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Cao LQ, Shao ZL, Liang HH, Zhang DW, Yang
XW, Jiang XF and Xue P: Activation of peroxisome
proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell
growth via downregulation of SEPT2 expression. Cancer Lett.
359:127–135. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pagliuso A, Tham TN, Stevens JK, Lagache
T, Persson R, Salles A, Olivo-Marin JC, Oddos S, Spang A, Cossart P
and Stavru F: A role for septin 2 in Drp1-mediated mitochondrial
fission. EMBO Rep. 17:858–873. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yu W, Ding X, Chen F, Liu M, Shen S, Gu X
and Yu L: The phosphorylation of SEPT2 on Ser218 by casein kinase 2
is important to hepatoma carcinoma cell proliferation. Mol Cell
Biochem. 325:61–67. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Xu D, Liu A, Wang X, Chen Y, Shen Y, Tan Z
and Qiu M: Repression of Septin9 and Septin2 suppresses tumor
growth of human glioblastoma cells. Cell Death Dis. 9:5142018.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sun QC, Zhong L, Qiu B, Zhao T and Zhou
XH: Expression of Septin2 in Hodgkin lymphoma cell line L428 and
its role in promoting H/RS cells' redifferentiation to B
lymphocytes. Zhonghua Xue Ye Xue Za Zhi. 38:134–139. 2017.(In
Chinese). PubMed/NCBI
|
|
26
|
Calvo F, Ranftl R, Hooper S, Farrugia AJ,
Moeendarbary E, Bruckbauer A, Batista F, Charras G and Sahai E:
Cdc42EP3/BORG2 and Septin Network Enables Mechano-transduction and
the emergence of cancer-associated fibroblasts. Cell Rep.
13:2699–2714. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kremer BE, Adang LA and Macara IG: Septins
regulate actin organization and cell-cycle arrest through nuclear
accumulation of NCK mediated by SOCS7. Cell. 130:837–850. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Spiliotis ET, Hunt SJ, Hu Q, Kinoshita M
and Nelson WJ: Epithelial polarity requires septin coupling of
vesicle transport to polyglutamylated microtubules. J Cell Biol.
180:295–303. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hu Q, Nelson WJ and Spiliotis ET:
Forchlorfenuron alters mammalian septin assembly, organization, and
dynamics. J Biol Chem. 283:29563–29571. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Tóth K, Galamb O, Spisák S, Wichmann B,
Sipos F, Valcz G, Leiszter K, Molnár B and Tulassay Z: The
influence of methylated septin 9 gene on RNA and protein level in
colorectal cancer. Pathol Oncol Res. 17:503–509. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Warren JD, Xiong W, Bunker AM, Vaughn CP,
Furtado LV, Roberts WL, Fang JC, Samowitz WS and Heichman KA:
Septin 9 methylated DNA is a sensitive and specific blood test for
colorectal cancer. BMC Med. 9:1332011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Grützmann R, Molnar B, Pilarsky C,
Habermann JK, Schlag PM, Saeger HD, Miehlke S, Stolz T, Model F,
Roblick UJ, et al: Sensitive detection of colorectal cancer in
peripheral blood by septin 9 DNA methylation assay. PLoS One.
3:e37592008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen CH, Yan SL, Yang TH, Chen SF, Yeh YH,
Ou JJ, Lin CH, Lee YT and Chen CH: The relationship between the
methylated septin-9 DNA blood test and stool occult blood test for
diagnosing colorectal cancer in taiwanese people. J Clin Lab Anal.
31:2017. View Article : Google Scholar
|
|
34
|
Zhang M, He Y, Zhang X, Zhang M and Kong
L: A pooled analysis of the diagnostic efficacy of plasmic
methylated septin-9 as a novel biomarker for colorectal cancer.
Biomed Rep. 7:353–360. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Rhodes DR, Kalyana-Sundaram S, Mahavisno
V, Varambally R, Yu J, Briggs BB, Barrette TR, Anstet MJ,
Kincead-Beal C, Kulkarni P, et al: Oncomine 3.0: Genes, pathways,
and networks in a collection of 18,000 cancer gene expression
profiles. Neoplasia. 9:166–180. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Rhodes DR, Yu J, Shanker K, Deshpande N,
Varambally R, Ghosh D, Barrette T, Pandey A and Chinnaiyan AM:
ONCOMINE: A cancer microarray database and integrated data-mining
platform. Neoplasia. 6:1–6. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Hong Y, Downey T, Eu KW, Koh PK and Cheah
PY: A ‘metastasis-prone’ signature for early-stage mismatch-repair
proficient sporadic colorectal cancer patients and its implications
for possible therapeutics. Clin Exp Metastasis. 27:83–90. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Skrzypczak M, Goryca K, Rubel T, Paziewska
A, Mikula M, Jarosz D, Pachlewski J, Oledzki J and Ostrowski J:
Modeling oncogenic signaling in colon tumors by multidirectional
analyses of microarray data directed for maximization of analytical
reliability. PLoS One. 5(pii): e130912010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kim DS, Hubbard SL, Peraud A, Salhia B,
Sakai K and Rutka JT: Analysis of mammalian septin expression in
human malignant brain tumors. Neoplasia. 6:168–178. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhang N, Liu L, Fan N, Zhang Q, Wang W,
Zheng M, Ma L, Li Y and Shi L: The requirement of SEPT2 and SEPT7
for migration and invasion in human breast cancer via MEK/ERK
activation. Oncotarget. 7:61587–61600. 2016.PubMed/NCBI
|
|
41
|
Friday BB and Adjei AA: Advances in
targeting the Ras/Raf/MEK/Erk mitogen-activated protein kinase
cascade with MEK inhibitors for cancer therapy. Clin Cancer Res.
14:342–346. 2008. View Article : Google Scholar : PubMed/NCBI
|
